Cytoreduction with hyperthermic intraperitoneal chemotherapy

an appraisal of outcomes and cost at a newly established peritoneal malignancy program

Nathan M. Hinkle, James MacDonald, John P. Sharpe, Paxton Dickson, Jeremiah Deneve, Gitonga Munene

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Outcome measures after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis in established centers are well defined. However, results from newly emerging US centers have not been reported. Methods This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Results Fifty-six patients underwent exploratory laparotomy with 36 receiving CRS/HIPEC over 36 months. The median peritoneal cancer index score was 18, and the cytoreduction 0/1 rate was 92%. Postoperative major morbidity was 16.7% with one perioperative death. The median length of hospital stay and intensive care unit days were 9 and 3 days, respectively. Disease-free survival in high-grade vs low-grade tumors was 12.6 and 31.0 months (P, .03), respectively. Average direct cost for patients undergoing CRS/HIPEC was $25,917. Conclusions Our emerging center's short-term results are comparable with established programs with a trend toward more selective intraoperative judgment on who undergoes CRS/HIPEC.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalAmerican Journal of Surgery
Volume212
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Costs and Cost Analysis
Drug Therapy
Neoplasms
Length of Stay
Laparotomy
Disease-Free Survival
Intensive Care Units
Outcome Assessment (Health Care)
Databases
Morbidity
Carcinoma

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Cytoreduction with hyperthermic intraperitoneal chemotherapy : an appraisal of outcomes and cost at a newly established peritoneal malignancy program. / Hinkle, Nathan M.; MacDonald, James; Sharpe, John P.; Dickson, Paxton; Deneve, Jeremiah; Munene, Gitonga.

In: American Journal of Surgery, Vol. 212, No. 3, 01.09.2016, p. 413-418.

Research output: Contribution to journalArticle

Hinkle, Nathan M. ; MacDonald, James ; Sharpe, John P. ; Dickson, Paxton ; Deneve, Jeremiah ; Munene, Gitonga. / Cytoreduction with hyperthermic intraperitoneal chemotherapy : an appraisal of outcomes and cost at a newly established peritoneal malignancy program. In: American Journal of Surgery. 2016 ; Vol. 212, No. 3. pp. 413-418.
@article{7237baa450b84a17aa521d2961532eaa,
title = "Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program",
abstract = "Background Outcome measures after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis in established centers are well defined. However, results from newly emerging US centers have not been reported. Methods This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Results Fifty-six patients underwent exploratory laparotomy with 36 receiving CRS/HIPEC over 36 months. The median peritoneal cancer index score was 18, and the cytoreduction 0/1 rate was 92{\%}. Postoperative major morbidity was 16.7{\%} with one perioperative death. The median length of hospital stay and intensive care unit days were 9 and 3 days, respectively. Disease-free survival in high-grade vs low-grade tumors was 12.6 and 31.0 months (P, .03), respectively. Average direct cost for patients undergoing CRS/HIPEC was $25,917. Conclusions Our emerging center's short-term results are comparable with established programs with a trend toward more selective intraoperative judgment on who undergoes CRS/HIPEC.",
author = "Hinkle, {Nathan M.} and James MacDonald and Sharpe, {John P.} and Paxton Dickson and Jeremiah Deneve and Gitonga Munene",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.amjsurg.2016.01.022",
language = "English (US)",
volume = "212",
pages = "413--418",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cytoreduction with hyperthermic intraperitoneal chemotherapy

T2 - an appraisal of outcomes and cost at a newly established peritoneal malignancy program

AU - Hinkle, Nathan M.

AU - MacDonald, James

AU - Sharpe, John P.

AU - Dickson, Paxton

AU - Deneve, Jeremiah

AU - Munene, Gitonga

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background Outcome measures after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis in established centers are well defined. However, results from newly emerging US centers have not been reported. Methods This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Results Fifty-six patients underwent exploratory laparotomy with 36 receiving CRS/HIPEC over 36 months. The median peritoneal cancer index score was 18, and the cytoreduction 0/1 rate was 92%. Postoperative major morbidity was 16.7% with one perioperative death. The median length of hospital stay and intensive care unit days were 9 and 3 days, respectively. Disease-free survival in high-grade vs low-grade tumors was 12.6 and 31.0 months (P, .03), respectively. Average direct cost for patients undergoing CRS/HIPEC was $25,917. Conclusions Our emerging center's short-term results are comparable with established programs with a trend toward more selective intraoperative judgment on who undergoes CRS/HIPEC.

AB - Background Outcome measures after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis in established centers are well defined. However, results from newly emerging US centers have not been reported. Methods This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Results Fifty-six patients underwent exploratory laparotomy with 36 receiving CRS/HIPEC over 36 months. The median peritoneal cancer index score was 18, and the cytoreduction 0/1 rate was 92%. Postoperative major morbidity was 16.7% with one perioperative death. The median length of hospital stay and intensive care unit days were 9 and 3 days, respectively. Disease-free survival in high-grade vs low-grade tumors was 12.6 and 31.0 months (P, .03), respectively. Average direct cost for patients undergoing CRS/HIPEC was $25,917. Conclusions Our emerging center's short-term results are comparable with established programs with a trend toward more selective intraoperative judgment on who undergoes CRS/HIPEC.

UR - http://www.scopus.com/inward/record.url?scp=84964330845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964330845&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2016.01.022

DO - 10.1016/j.amjsurg.2016.01.022

M3 - Article

VL - 212

SP - 413

EP - 418

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 3

ER -